FY2029 Earnings Estimate for DWTX Issued By HC Wainwright

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Stock analysts at HC Wainwright reduced their FY2029 EPS estimates for Dogwood Therapeutics in a research report issued on Friday, August 14th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of $0.52 per share for the year, down from their prior estimate of $0.55. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ FY2030 earnings at $1.29 EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20).

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Stock Performance

DWTX opened at $2.06 on Monday. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $9.50. The company has a market cap of $69.28 million, a P/E ratio of -0.23 and a beta of 1.71. The business’s 50-day simple moving average is $1.58 and its 200-day simple moving average is $2.03.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.